Allogene Therapeutics (ALLO) Long-Term Investments (2019 - 2025)
Historic Long-Term Investments for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $24.9 million.
- Allogene Therapeutics' Long-Term Investments fell 7769.29% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 7769.29%. This contributed to the annual value of $80.7 million for FY2024, which is 211325.1% up from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Long-Term Investments is $24.9 million, which was down 7769.29% from $29.5 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Long-Term Investments high stood at $378.2 million for Q3 2021, and its period low was $1.1 million during Q2 2024.
- Over the past 5 years, Allogene Therapeutics' median Long-Term Investments value was $59.2 million (recorded in 2022), while the average stood at $125.9 million.
- Its Long-Term Investments has fluctuated over the past 5 years, first tumbled by 9784.35% in 2024, then soared by 250229.28% in 2025.
- Allogene Therapeutics' Long-Term Investments (Quarter) stood at $352.2 million in 2021, then tumbled by 83.2% to $59.2 million in 2022, then plummeted by 93.84% to $3.6 million in 2023, then surged by 2113.25% to $80.7 million in 2024, then plummeted by 69.08% to $24.9 million in 2025.
- Its last three reported values are $24.9 million in Q3 2025, $29.5 million for Q2 2025, and $55.5 million during Q1 2025.